Diabetes is a prolonged, enduring disease characterized by high blood glucose level arising when the pancreas are no longer capable to secrete insulin: a key hormone that processes glucose to produce energy. Inability to produce insulin or use it effectively leads to the raised glucose level in the blood (hyperglycemia). Over long term, high blood glucose level can damage the blood vessels in the heart, kidneys, eyes or the nervous system. The global diabetes drugs market is emerging at an impressive pace because of intensifying diabetes population leading to increasing demand for diabetic care. Apart from availability of an array of existing drugs, widespread R&D projects for new diabetes investigative methods has given industry a boost.
This research study titled Diabetes Drugs Market - Growth, Future Prospects, and Competitive Analysis, 2022 - 2030 states the detailed analysis which helps investors, developers, company executives and industry participants in making decisions related to the prospects in the global diabetes drugs market and to take strategic initiatives. This report examines and offers the foremost trends prevalent in the global diabetes drugs market and the market size and forecast.
The scope of the report comprises types of therapy and geographical distribution. The types of therapy segments are further categorized into insulin, oral hypoglycemic drugs (anti-diabetic drugs), non-insulin injectable anti-diabetes drugs, and others. In-depth analysis in terms of market size and forecast is done for each segment for the duration 2020-2030, alongside particular CAGRs for the duration 2022-2030 is also presented in the report.
A description of the market estimation of the above-mentioned segment for the duration 2020-2030 is covered in the scope of the report along with the individual market estimation for the respective countries in the regional segments.
A comprehensive description is also been presented regarding the market dynamics in the report to understand and anticipate the trends in the market. Tools for conducting a portfolio analysis by the key player are also demonstrated in the reports. This report also incorporates the company profiling of the major market players which holds the prominent position in the diabetes drugs market globally. The major players in global diabetes drugs market are AstraZeneca plc, Biocon Limited, Boston Therapeutics, Inc., Cadila Healthcare, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Lupin Limited, Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Ranbaxy Laboratories Limited, Sanofi S.A., Takeda Pharmaceutical Company Ltd., among others.
Diabetes medicine is a general treatment for the people who are suffering from diabetes. Various types of diabetes or anti-diabetes drugs are available, having their own area of action which help the patient to keep the condition under control. The way of delivery may differ, some injected directly into blood and some drugs taken orally. The global diabetes drugs market is emerging at impressive pace because of intensifying diabetic population growth, aging, unhealthy diets, obesity, and sedentary lifestyle resulting in increasing demand for diabetic drugs and enhancing the market size.
Geographically, the global diabetes drugs market is cumulative to Europe, North America, Asia Pacific, Middle East and Africa and Latin America.
In 2021, North America & Europe have accounted for the major share in global diabetes drugs market followed by Asia Pacific due to key driving factors such as rising prevalence of diabetes, high awareness associated with early diabetes diagnosis and treatment, and supportive reimbursement policies. The International Diabetes Federation estimates that in 2021 about 82 million people were diagnosed in Asia Pacific and about 1.1 million deaths occurred. Due to perpetual growth in incidence of diabetes, the demand for novel drug therapies are expected to increase in the near future. During forecast period 2022 - 2030, Asia Pacific was observed as the fastest growing region due to key driving factors such as rising prevalence of diabetes in developing countries, increasing awareness associated with early diabetes diagnosis, developing healthcare infrastructure, and mounting demand for novel drug therapies.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
This product will be delivered within 2 business days.
This research study titled Diabetes Drugs Market - Growth, Future Prospects, and Competitive Analysis, 2022 - 2030 states the detailed analysis which helps investors, developers, company executives and industry participants in making decisions related to the prospects in the global diabetes drugs market and to take strategic initiatives. This report examines and offers the foremost trends prevalent in the global diabetes drugs market and the market size and forecast.
The scope of the report comprises types of therapy and geographical distribution. The types of therapy segments are further categorized into insulin, oral hypoglycemic drugs (anti-diabetic drugs), non-insulin injectable anti-diabetes drugs, and others. In-depth analysis in terms of market size and forecast is done for each segment for the duration 2020-2030, alongside particular CAGRs for the duration 2022-2030 is also presented in the report.
A description of the market estimation of the above-mentioned segment for the duration 2020-2030 is covered in the scope of the report along with the individual market estimation for the respective countries in the regional segments.
A comprehensive description is also been presented regarding the market dynamics in the report to understand and anticipate the trends in the market. Tools for conducting a portfolio analysis by the key player are also demonstrated in the reports. This report also incorporates the company profiling of the major market players which holds the prominent position in the diabetes drugs market globally. The major players in global diabetes drugs market are AstraZeneca plc, Biocon Limited, Boston Therapeutics, Inc., Cadila Healthcare, Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, Lupin Limited, Merck & Co., Inc., Novartis International AG, Pfizer, Inc., Ranbaxy Laboratories Limited, Sanofi S.A., Takeda Pharmaceutical Company Ltd., among others.
By type of therapy analysis
In 2021, insulin dominated the market due to continuous market entry of novel drug therapies, most convenient mode of treatment, and rising demand for targeted therapy/biological drugs. The growth of diabetes drugs market has been strongly supported by novel drug therapies like anti-diabetes drugs and more. One major factor that contributes to the growth of diabetes drugs is increased life expectancy. As the populations are rapidly aging, the incidence and prevalence of many chronic diseases degeneration are bound to increase correspondingly, thus driving the growth in demand for diabetes drugs. Additionally, it is not just geriatric population that is making the choice for diabetes drugs, but increasing incidence is also being noticed in adolescents, which is also supporting the growth of the market.Diabetes medicine is a general treatment for the people who are suffering from diabetes. Various types of diabetes or anti-diabetes drugs are available, having their own area of action which help the patient to keep the condition under control. The way of delivery may differ, some injected directly into blood and some drugs taken orally. The global diabetes drugs market is emerging at impressive pace because of intensifying diabetic population growth, aging, unhealthy diets, obesity, and sedentary lifestyle resulting in increasing demand for diabetic drugs and enhancing the market size.
Geographically, the global diabetes drugs market is cumulative to Europe, North America, Asia Pacific, Middle East and Africa and Latin America.
In 2021, North America & Europe have accounted for the major share in global diabetes drugs market followed by Asia Pacific due to key driving factors such as rising prevalence of diabetes, high awareness associated with early diabetes diagnosis and treatment, and supportive reimbursement policies. The International Diabetes Federation estimates that in 2021 about 82 million people were diagnosed in Asia Pacific and about 1.1 million deaths occurred. Due to perpetual growth in incidence of diabetes, the demand for novel drug therapies are expected to increase in the near future. During forecast period 2022 - 2030, Asia Pacific was observed as the fastest growing region due to key driving factors such as rising prevalence of diabetes in developing countries, increasing awareness associated with early diabetes diagnosis, developing healthcare infrastructure, and mounting demand for novel drug therapies.
Historical & Forecast Period
This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Diabetes Drugs market are as follows:- Research and development budgets of manufacturers and government spending
- Revenues of key companies in the market segment
- Number of end users and consumption volume, price and value.
- Geographical revenues generate by countries considered in the report
- Micro and macro environment factors that are currently influencing the Diabetes Drugs market and their expected impact during the forecast period.
Market Segmentation
Therapy
- Insulin
- Oral Hypoglycemic Drugs (anti-diabetes drugs)
- Non-insulin Injectable Anti-diabetes Drugs
- Others
- Phase III (Market estimations by 2029)
- ISLETS (National Institute of Health (NID) & Health Resource and Services Administration)
- ORMD-0801 or Placebo (Oramed, Ltd. & Integrium)
- Tauroursodeoxycholic Acid (TUDCA) (Juvenile Diabetes Research Foundation)
- Others
- Tabular Presentation of Phase II (Qualitative Information)
- Tabular Presentation of Phase Phase I (Qualitative Information)
Key questions answered in this report
- What are the key micro and macro environmental factors that are impacting the growth of Diabetes Drugs market?
- What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
- Estimated forecast and market projections up to 2030.
- Which segment accounts for the fastest CAGR during the forecast period?
- Which market segment holds a larger market share and why?
- Are low and middle-income economies investing in the Diabetes Drugs market?
- Which is the largest regional market for Diabetes Drugs market?
- What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
- Which are the key trends driving Diabetes Drugs market growth?
- Who are the key competitors and what are their key strategies to enhance their market presence in the Diabetes Drugs market worldwide?
This product will be delivered within 2 business days.
Table of Contents
1. Preface1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted
2. Executive Summary
2.1. Market Snapshot: Global Diabetes Drugs Market
2.2. Global Diabetes Drugs Market, By Therapy, 2021 (US$ Million)
2.3. Global Diabetes Drugs Market, By Geography, 2021 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2021
3. Diabetes Drugs Market: Competitive Analysis
3.1. Market Positioning of Key Diabetes Drugs Market Vendors
3.2. Strategies Adopted by Diabetes Drugs Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030
4. Diabetes Drugs Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Diabetes Drugs Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
5. Diabetes Drugs Market: By Therapy, 2020-2030, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
5.3.1. Insulin
5.3.2. Oral Hypoglycemic Drugs (anti-diabetes drugs)
5.3.3. Non-insulin Injectable Anti-diabetes Drugs
5.3.4. Others
5.3.5. Phase III (Market estimations by 2029)
5.3.5.1. ISLETS (National Institute of Health (NID) & Health Resource and Services Administration)
5.3.5.2. ORMD-0801 or Placebo (Oramed, Ltd. & Integrium)
5.3.5.3. Tauroursodeoxycholic Acid (TUDCA) (Juvenile Diabetes Research Foundation)
5.3.5.4. Others
5.3.6. Tabular Presentation of Phase II (Qualitative Information)
5.3.7. Tabular Presentation of Phase Phase I (Qualitative Information)
6. North America Diabetes Drugs Market, 2020-2030, USD (Million)
6.1. Market Overview
6.2. Diabetes Drugs Market: By Therapy, 2020-2030, USD (Million)
6.3.Diabetes Drugs Market: By Region, 2020-2030, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Diabetes Drugs Market: By Therapy, 2020-2030, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Diabetes Drugs Market: By Therapy, 2020-2030, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Diabetes Drugs Market: By Therapy, 2020-2030, USD (Million)
7. UK and European Union Diabetes Drugs Market, 2020-2030, USD (Million)
7.1. Market Overview
7.2. Diabetes Drugs Market: By Therapy, 2020-2030, USD (Million)
7.3.Diabetes Drugs Market: By Region, 2020-2030, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Diabetes Drugs Market: By Therapy, 2020-2030, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Diabetes Drugs Market: By Therapy, 2020-2030, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Diabetes Drugs Market: By Therapy, 2020-2030, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Diabetes Drugs Market: By Therapy, 2020-2030, USD (Million)
7.3.1.5. France
7.3.1.5.1. Diabetes Drugs Market: By Therapy, 2020-2030, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Diabetes Drugs Market: By Therapy, 2020-2030, USD (Million)
8. Asia Pacific Diabetes Drugs Market, 2020-2030, USD (Million)
8.1. Market Overview
8.2. Diabetes Drugs Market: By Therapy, 2020-2030, USD (Million)
8.3.Diabetes Drugs Market: By Region, 2020-2030, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Diabetes Drugs Market: By Therapy, 2020-2030, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Diabetes Drugs Market: By Therapy, 2020-2030, USD (Million)
8.3.1.3. India
8.3.1.3.1. Diabetes Drugs Market: By Therapy, 2020-2030, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Diabetes Drugs Market: By Therapy, 2020-2030, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Diabetes Drugs Market: By Therapy, 2020-2030, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Diabetes Drugs Market: By Therapy, 2020-2030, USD (Million)
9. Latin America Diabetes Drugs Market, 2020-2030, USD (Million)
9.1. Market Overview
9.2. Diabetes Drugs Market: By Therapy, 2020-2030, USD (Million)
9.3.Diabetes Drugs Market: By Region, 2020-2030, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Diabetes Drugs Market: By Therapy, 2020-2030, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Diabetes Drugs Market: By Therapy, 2020-2030, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Diabetes Drugs Market: By Therapy, 2020-2030, USD (Million)
10. Middle East and Africa Diabetes Drugs Market, 2020-2030, USD (Million)
10.1. Market Overview
10.2. Diabetes Drugs Market: By Therapy, 2020-2030, USD (Million)
10.3.Diabetes Drugs Market: By Region, 2020-2030, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Diabetes Drugs Market: By Therapy, 2020-2030, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Diabetes Drugs Market: By Therapy, 2020-2030, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Diabetes Drugs Market: By Therapy, 2020-2030, USD (Million)
11. Company Profile
11.1. AstraZeneca plc
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. Biocon Limited
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. Boston Therapeutics, Inc.
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Cadila Healthcare
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Eli Lilly and Company
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. GlaxoSmithKline plc
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Johnson & Johnson
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Lupin Limited
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Merck & Co., Inc.
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives
11.10. Novartis International AG
11.10.1. Company Overview
11.10.2. Financial Performance
11.10.3. Product Portfolio
11.10.4. Strategic Initiatives
11.11. Pfizer Inc.
11.11.1. Company Overview
11.11.2. Financial Performance
11.11.3. Product Portfolio
11.11.4. Strategic Initiatives
11.12. Ranbaxy Laboratories Limited
11.12.1. Company Overview
11.12.2. Financial Performance
11.12.3. Product Portfolio
11.12.4. Strategic Initiatives
11.13. Sanofi S.A.
11.13.1. Company Overview
11.13.2. Financial Performance
11.13.3. Product Portfolio
11.13.4. Strategic Initiatives
11.14. Takeda Pharmaceutical Company Ltd.
11.14.1. Company Overview
11.14.2. Financial Performance
11.14.3. Product Portfolio
11.14.4. Strategic Initiatives
List of Figures
Figure 1 Global Diabetes Drugs Market: Market Coverage
Figure 2 Research Methodology and Data Sources
Figure 3 Market Size Estimation - Top Down & Bottom-Up Approach
Figure 4 Global Diabetes Drugs Market: Quality Assurance
Figure 5 Global Diabetes Drugs Market, By Therapy, 2021
Figure 6 Global Diabetes Drugs Market, By Geography, 2021
Figure 7 Market Geographical Opportunity Matrix - Global Diabetes Drugs Market, 2021
Figure 8 Market Positioning of Key Diabetes Drugs Market Players, 2021
Figure 9 Global Diabetes Drugs Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
Figure 10 Global Diabetes Drugs Market, By Therapy, 2021 Vs 2030, %
Figure 11 U.S. Diabetes Drugs Market (US$ Million), 2020 - 2030
Figure 12 Canada Diabetes Drugs Market (US$ Million), 2020 - 2030
Figure 13 Rest of North America Diabetes Drugs Market (US$ Million), 2020 - 2030
Figure 14 UK Diabetes Drugs Market (US$ Million), 2020 - 2030
Figure 15 Germany Diabetes Drugs Market (US$ Million), 2020 - 2030
Figure 16 Spain Diabetes Drugs Market (US$ Million), 2020 - 2030
Figure 17 Italy Diabetes Drugs Market (US$ Million), 2020 - 2030
Figure 18 France Diabetes Drugs Market (US$ Million), 2020 - 2030
Figure 19 Rest of Europe Diabetes Drugs Market (US$ Million), 2020 - 2030
Figure 20 China Diabetes Drugs Market (US$ Million), 2020 - 2030
Figure 21 Japan Diabetes Drugs Market (US$ Million), 2020 - 2030
Figure 22 India Diabetes Drugs Market (US$ Million), 2020 - 2030
Figure 23 Australia Diabetes Drugs Market (US$ Million), 2020 - 2030
Figure 24 South Korea Diabetes Drugs Market (US$ Million), 2020 - 2030
Figure 25 Rest of Asia Diabetes Drugs Market (US$ Million), 2020 - 2030
Figure 26 Brazil Diabetes Drugs Market (US$ Million), 2020 - 2030
Figure 27 Mexico Diabetes Drugs Market (US$ Million), 2020 - 2030
Figure 28 Rest of Latin America Diabetes Drugs Market (US$ Million), 2020 - 2030
Figure 29 GCC Diabetes Drugs Market (US$ Million), 2020 - 2030
Figure 30 Africa Diabetes Drugs Market (US$ Million), 2020 - 2030
Figure 31 Rest of Middle East and Africa Diabetes Drugs Market (US$ Million), 2020 - 2030
List of Tables
Table 1 Global Diabetes Drugs Market By Therapy, 2020-2030, USD (Million)
Table 2 Global Diabetes Drugs Market By Phase III (Market estimations by 2029), 2020-2030, USD (Million)
Table 3 North America Diabetes Drugs Market By Therapy, 2020-2030, USD (Million)
Table 4 North America Diabetes Drugs Market By Phase III (Market estimations by 2029), 2020-2030, USD (Million)
Table 5 U.S. Diabetes Drugs Market By Therapy, 2020-2030, USD (Million)
Table 6 U.S. Diabetes Drugs Market By Phase III (Market estimations by 2029), 2020-2030, USD (Million)
Table 7 Canada Diabetes Drugs Market By Therapy, 2020-2030, USD (Million)
Table 8 Canada Diabetes Drugs Market By Phase III (Market estimations by 2029), 2020-2030, USD (Million)
Table 9 Rest of North America Diabetes Drugs Market By Therapy, 2020-2030, USD (Million)
Table 10 Rest of North America Diabetes Drugs Market By Phase III (Market estimations by 2029), 2020-2030, USD (Million)
Table 11 UK and European Union Diabetes Drugs Market By Therapy, 2020-2030, USD (Million)
Table 12 UK and European Union Diabetes Drugs Market By Phase III (Market estimations by 2029), 2020-2030, USD (Million)
Table 13 UK Diabetes Drugs Market By Therapy, 2020-2030, USD (Million)
Table 14 UK Diabetes Drugs Market By Phase III (Market estimations by 2029), 2020-2030, USD (Million)
Table 15 Germany Diabetes Drugs Market By Therapy, 2020-2030, USD (Million)
Table 16 Germany Diabetes Drugs Market By Phase III (Market estimations by 2029), 2020-2030, USD (Million)
Table 17 Spain Diabetes Drugs Market By Therapy, 2020-2030, USD (Million)
Table 18 Spain Diabetes Drugs Market By Phase III (Market estimations by 2029), 2020-2030, USD (Million)
Table 19 Italy Diabetes Drugs Market By Therapy, 2020-2030, USD (Million)
Table 20 Italy Diabetes Drugs Market By Phase III (Market estimations by 2029), 2020-2030, USD (Million)
Table 21 France Diabetes Drugs Market By Therapy, 2020-2030, USD (Million)
Table 22 France Diabetes Drugs Market By Phase III (Market estimations by 2029), 2020-2030, USD (Million)
Table 23 Rest of Europe Diabetes Drugs Market By Therapy, 2020-2030, USD (Million)
Table 24 Rest of Europe Diabetes Drugs Market By Phase III (Market estimations by 2029), 2020-2030, USD (Million)
Table 25 Asia Diabetes Drugs Market By Therapy, 2020-2030, USD (Million)
Table 26 Asia Diabetes Drugs Market By Phase III (Market estimations by 2029), 2020-2030, USD (Million)
Table 27 China Diabetes Drugs Market By Therapy, 2020-2030, USD (Million)
Table 28 China Diabetes Drugs Market By Phase III (Market estimations by 2029), 2020-2030, USD (Million)
Table 29 Japan Diabetes Drugs Market By Therapy, 2020-2030, USD (Million)
Table 30 Japan Diabetes Drugs Market By Phase III (Market estimations by 2029), 2020-2030, USD (Million)
Table 31 India Diabetes Drugs Market By Therapy, 2020-2030, USD (Million)
Table 32 India Diabetes Drugs Market By Phase III (Market estimations by 2029), 2020-2030, USD (Million)
Table 33 Australia Diabetes Drugs Market By Therapy, 2020-2030, USD (Million)
Table 34 Australia Diabetes Drugs Market By Phase III (Market estimations by 2029), 2020-2030, USD (Million)
Table 35 South Korea Diabetes Drugs Market By Therapy, 2020-2030, USD (Million)
Table 36 South Korea Diabetes Drugs Market By Phase III (Market estimations by 2029), 2020-2030, USD (Million)
Table 37 Latin America Diabetes Drugs Market By Therapy, 2020-2030, USD (Million)
Table 38 Latin America Diabetes Drugs Market By Phase III (Market estimations by 2029), 2020-2030, USD (Million)
Table 39 Brazil Diabetes Drugs Market By Therapy, 2020-2030, USD (Million)
Table 40 Brazil Diabetes Drugs Market By Phase III (Market estimations by 2029), 2020-2030, USD (Million)
Table 41 Mexico Diabetes Drugs Market By Therapy, 2020-2030, USD (Million)
Table 42 Mexico Diabetes Drugs Market By Phase III (Market estimations by 2029), 2020-2030, USD (Million)
Table 43 Rest of Latin America Diabetes Drugs Market By Therapy, 2020-2030, USD (Million)
Table 44 Rest of Latin America Diabetes Drugs Market By Phase III (Market estimations by 2029), 2020-2030, USD (Million)
Table 45 Middle East and Africa Diabetes Drugs Market By Therapy, 2020-2030, USD (Million)
Table 46 Middle East and Africa Diabetes Drugs Market By Phase III (Market estimations by 2029), 2020-2030, USD (Million)
Table 47 GCC Diabetes Drugs Market By Therapy, 2020-2030, USD (Million)
Table 48 GCC Diabetes Drugs Market By Phase III (Market estimations by 2029), 2020-2030, USD (Million)
Table 49 Africa Diabetes Drugs Market By Therapy, 2020-2030, USD (Million)
Table 50 Africa Diabetes Drugs Market By Phase III (Market estimations by 2029), 2020-2030, USD (Million)
Table 51 Rest of Middle East and Africa Diabetes Drugs Market By Therapy, 2020-2030, USD (Million)
Table 52 Rest of Middle East and Africa Diabetes Drugs Market By Phase III (Market estimations by 2029), 2020-2030, USD (Million)
Companies Mentioned
- AstraZeneca plc
- Biocon Limited
- Boston Therapeutics Inc.
- Cadila Healthcare
- Eli Lilly and Company
- GlaxoSmithKline plc
- Johnson & Johnson
- Lupin Limited
- Merck & Co. Inc.
- Novartis International AG
- Pfizer Inc.
- Ranbaxy Laboratories Limited
- Sanofi S.A.
- Takeda Pharmaceutical Company Ltd.
